Member Info for AquaeSulis01

Heartening to hear about the success of the product for both your daughter and yourself Toyin from both your health and investor perspective. Elrico may well have already posed the question re website wording on behalf of shareholders, I will see whether he comments or not, but happy to contact the company otherwise.

Hi Toyin, first let me emphasise I am talking about the wording on the Axisbiotix Ltd website which I suspect covers this specific blend of axisbiotix product and future anticipated blends (think Optis Cholbiome bp, cholbiome vh) to target other "psoriatic like" skin conditions such as (and I refer to the Bright Study list) acne, eczema, contact dermatitis, and rosacea, not the wording on the Axisbiotix product packaging itself which appears to be what your link refers to. Hence I believe that the wording on the website appears to have been chosen with the generic brand of axisbiotix (current and future) in mind rather than this specific psoriatic designed blend of axisbiotix rather than with any legal rules in mind. Indeed, if you think about it, as the Bright Study only states that "177 reported that they had psoriasis, 42 reported that they
had psoriasis and some other skin condition, and 48 reported that they had a skin condition different from
psoriasis, such as eczema, acne, rosacea or contact dermatitis. This report focuses on the results obtained for the
participants with psoriasis only." but then only produces the results for the 91 people with psoriasis that completed the study, it could be said that wording that infers axisbiotix alleviates skin conditions like psoriasis, is more misleading than saying it has shown to alleviate psoriasis itself because the company has only recorded anecdotal evidence for the latter.
The reason that I feel so strongly about the website wording is that all the marketing is targeted at the psoriatic community via adverts and influencers, someone with acne or eczema will never find this site as it does not flag up on google searches etc. So all the wording on the website needs to be specific to psoriasis until such time as new blends are produced targeted at other communities. After all, a person with psoriasis will be interested in whether it is likely to help with their type of psoriasis not a condition like psoriasis
https://www.nhs.uk/conditions/psoriasis/symptoms/

https://m.facebook.com/AxisBiotix/posts/198674208961907 See the reply to Scott. Perhaps when they develop the blend to specifically target acne they will advertise that as addressing symptoms like acne as well which will also make it sound like snake oil

I disagree toyin it is a statement of fact.

The suggested change to the web para "By harnessing the link between gut and skin we have developed AxisBiotix-Ps - a food supplement made up of a bespoke blend of natural bacteria, scientifically selected to alleviate the symptoms of skin conditions like psoriasis." is merely to remove the words "skin conditions like" which should not fall foul of any good stuff rules.

elrico, I am well aware it was a consumer study but am unclear what your point is regarding the website wording differing from the launch of axisbiotix as a product for sell RNS wording? The latter makes it clear the probiotix mix is designed to alleviate psoriasis; this wording should also be reflected on the website in a prominent position, it does not of course, and should not go on to infer it is clinical proven which is a totally different claim.

Well if it is a Continental Europe company must surely be Bosch

Surprised that the sp hasn't rebounded by now after all, taking into account the Bank Holiday a 4 working day delay hardly smacks of anything significant. Maybe the Market is being very risk averse and making sure the results actually are delivered on Tuesday

rodders, the end customers have been trialling sweetbiotix in their products for a couple of years now, hence reference to premium royalties from their US partner if sales emminate from any of the dozen or so previously contacted by Opti.

This from 5th Aug 2021 update " Commercialising second generation products

a. SweetBiotix: The Company is progressing industrial scale up of a number of its innovative SweetBiotix products with its US partner and working with a number of corporates with leading positions in the Food & Beverages markets who have signed Material Transfer Agreements to develop applications."

Odd you should mention Tom because he is very good at calling out Frauds and over valued stocks so whilst this share continues to figure so prominently in his pension savings I am more than happy to remain invested

Does anyone else find it odd that the Axisbiotix website opening paragraph reads "By harnessing the link between gut and skin we have developed AxisBiotix-Ps - a food supplement made up of a bespoke blend of natural bacteria, scientifically selected to alleviate the symptoms of skin conditions like psoriasis."?
Now I thought that the blend was specifically put together to address the over production of new skincells associated with psoriasis, indeed the launch RNS reads "SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, has today provided a significant update on its commercialisation plans for AxisBiotix-Ps™, its probiotic food supplement to help alleviate the symptoms associated with psoriasis, and reveals the launch date as 29 October 2021, which notably is World Psoriasis Day."

So why not make it abundantly clear on the website that whilst over general skin improvements are likely to be seen it is primarily designed to tackle psoriasis so that potential new psoriatic customers are left in no doubt that it is not a general purpose catch all product

Don't forget there are quite a few assay reports awaited, from the last drilling update;

"ECR Minerals announced the identification of four soil anomalies respectively named (A, B, C and D) in the vicinity of the projected Scoulers and Hard-Up Reef lines (see RNS dated 23rd December 2021 “Bailieston (HR3) Soil Sampling Strengthens Mineralisation Model”). Two initial drillholes (BH3DD026 and BH3DD027) were drilled underneath soil anomaly ‘A’. Results for hole BH3DD027 have now been received with the results pending for BH3DD026."
"CHANGE OF ASSAY METHOD

Visible Stibnite (Antimony Sulphide) has been observed to occur in some of the drillholes into the Maori Anticline. As gold has been the primary mineral of interest, earlier assay results from the drilling have not been analysed for the Antimony content. Until recently, the preferred assay method has been to leach the bulk 2 kg drill sample using a cyanide solution. This is followed by fire assay of the residual tails from the solution, thereby tracing any potential undissolved coarser gold particles. With the increasing importance of Stibnite, the Company has refined the assay method to include such metals as Antimony. Additionally, all samples will have an initial 50g fire assay with only bulk leaching amendable to samples that show trace gold levels. This will save costs and speed up results without compromising quality of the assay.

CURRENT DRILLING PROGRESS

Drilling has now been completed into selected zones of both the upper and north end of the known Maori Reef. Geological logging is confirming our understanding of the Maori Anticline and how the main Reef systems consist of narrow stibnite-sulphide veining propagating up through the fold. Recently drilled BH3DD034 suggests gold mineralisation is still open along strike to the north. Assay results from this drilling will assist in follow-up drilling as needed.

Currently, the drilling programme is designed to investigate Scoulers Reef and associated soil anomalies which run along strike, parallel to the Maori Anticline. Some of the drillholes will be extended to target the Maori Anticline at depth to aid geological interpretation."

Where's sweetbiotix when you need it, any news yet SOH your market awaits?
https://www.mirror.co.uk/money/kelloggs-blasted-suing-government-over-26816447

Well that's not being very contrarian agreeing with the general market sentiment and following the herd on the BB. Live up to your name and buy against the market sentiment especially after the very good question posed by the PI and hedge fund manager regarding the poor presentation of the strategy and the response given

TV rules revamp offers more bargaining power to BBC, ITV and C4 https://worldnewsera.com/news/finance/tv-rules-revamp-offers-more-bargaining-power-to-bbc-itv-and-c4/

lord. on what do you base your statement that Skin are operating from a lower starting base from Opti? From the Opti Final Results for 2015 dated 14th Apr 2016, Revenue £26,200 for the whole year although it is not clear what generated that revenue, whilst the following fy reported 25th Apr 2017 resulted in revenue of £288119 from slimbiome but that followed a deal struck with KSF who owned slimfast in Jan 2016 and represented 11 mths worth of contribution, so far we have only had 2 mths of revenue to compare it to for axisbiotix during a soft launch so hardly a fair basis for judgement.
Incidentently, also from the 2016 Final Results RNS " SweetBiotix®



Work to date has demonstrated our ability to synthesise sweet calorie free natural healthy sugars (SweetBiotix®) with safety and sweetness confirmed by human taste studies. These sweet natural healthy sugars are not digested in the human gut and hence calorie free. The SweetBiotix concept is an innovative concept with the potential to address a global requirement, addressing international concerns over the impact of sugar on obesity, with the prospect of replacing 'unhealthy' sugars in existing products with non-digestible, low calorie, healthy, SweetBiotix®. As the food and beverage industry responds to growing public and political concerns over traditional sugars and artificial sweeteners, we anticipate high levels of commercial interest in this product. In anticipation of growing industry interest, we have accelerated our development plans and hope to launch our first generation sugar product later this year, or at the start of 2018." which perfectly illustrates the distrust people have with SOH forecasts unfortunately

Lord you are correct in that an awful lot of trust is being placed on future growth. Where I would say that Skin differs from Opti is that Opti have never explored the B2C route preferring to sell ingredients rather than products to Companies to incorporate into their own products. This has ked to a low starting base and average % increases in value year on year with forecast after forecast being missed and hence a loss of faith in Opti's future growth prospects. Slimbiome is also just one weight loss ingredient amongst many on the market. The recent Skin share price plunge quite rightly reflects Stuart's first missed target warning, however, the axisbiotix product appears to stand out from currently available alternative treatments, and Stuart has now put in place the necessary marketing team to promote the product to end customers; the retention rate of 70% augers well for a steady increase in subscription rates as it becomes more widely known amongst the psoriatic communities. That said we need to see the initial few weeks of influencer generated sales of 355% maintained over the coming weeks and months to quickly build the subscription base; so jury is out until we see the progress made from the soft launch.
We then come to Skin's equivalent of Opti's sweetbiotix second generation product; skinbiotix which we are told will be launched by Croda this year. If SOH was to announce that Sweetbiotix will definitely be launching in the next qtr then I dare say you would see a huge re-rate in the Opti share price, the problem is he has teased investors with hints of a launch for the last few years and nobody believes it is definitely going to happen anymore. So I would argue that skin's growth trajectory is understandably higher than Opti's, but that will only hold if Stuart doesn't slip on anymore of his forecasts.

Realistically, I am looking for subscriptions to be averaging 6000 per month by end of Jun generating revenue of £180,000 per month. I base this on the Mar half year update that informed us that subscriptions had risen by 335% by end Feb (circa 1580) and that the influencers were due to do a second round of promotions to another 100,000 followers so not unrealistic to hope for a further 335% increase on the Feb figures. So total income by end of Jun 22 may be closer to £600,000 than £1.2M but I would be happy with that.

Mad, the sales miss is not merely a timing issue, the company was never set up on a B2C basis but was always envisaged to be a B2B company like its parent Opti. The Covid situation led Stuart to move away from a clinical trial towards a consumer study and the enthusiasm of the NPF who describes themselves as "Partners" no doubt convinced Stuart, along with high expression of interest figures that did not materialise into sales, that he could meet the £1.2M by June revenue largely through word-of-mouth; this from the 30th Nov 2021 EOY results "The Group is pursuing a 'direct to consumer' commercialisation model for AxisBiotix-Ps™, selling the product through the website AxisBiotix.com. The psoriatic community is highly communicative regarding the condition and its treatment, therefore, management considers that engagement with sufferers both directly through social media and via the national psoriasis associations in the target country markets is an efficient and cost-effective way of penetrating the market.".

So now Stuart is having to play catch-up through the setting up of the influencer controlled sales team but that will take time. We know sales were only £21,949 at the end of Dec 21 = circa 365 subscribers, so to reach a revenue figure of £1.2M by Jun 22 would require subscribers to average 6667 per month from Jan 2022 or more realistically, expecting the impact of influencers to substantially increase subscribers from April, nearer 13,333 subscribers, which is unlikely to happen, hence the "material miss" reported in the half year results in March 2022.

So whilst the Opti share sale didn't help, it was the over hyped results that did the real damage to the share price, and it will be addressing those disappointing results that will repair the damage, along with other positive product news of course.

Trek, they are saying that they weren't bothered about testing for Antimony levels but the invasion of Ukraine has highlighted the importance of sourcing it from other locations than China and Russia I suspect.

https://www.forbes.com/sites/davidblackmon/2021/05/06/antimony-the-most-important-mineral-you-never-heard-of/